FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OWID ALT I	TOVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
3235-0287								
Estimated average burden								
0.5								

Name and Address of Reporting Person*     Thomsen Jillian B.																olicable) ctor er (give title	10% Other	Person(s) to Issuer  10% Owner  Other (specify		
(Last) (First) (Middle) C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH					3. Date of Earliest Transaction (Month/Day/Year) 11/16/2016									SVP & Chief Accounting Officer						
(Street) SAN FRANCISCO CA 94158  (City) (State) (Zip)							4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date					Execution (Year) if any		cution Date, ny							and 5) Secu Bene Own		ties cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									v	Amount	(A) (D)	or	Price		Transaction(s) (Instr. 3 and 4)					
Common Stock 11/16/20								S		1,986	D \$13.		\$13.9	96 <sup>(1)</sup> 42,102 <sup>(2)</sup>		2,102 <sup>(2)</sup>	D			
	Та													y Ov	vned					
ecurity or Exercise (Month/Day/Year) if any			on Date, Day/Year) _	Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration			Amour or Number of		f g nstr. 3 mount umber	Deriv Secu	rivative curity	derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
E .	(Stock  2. Conversion or Exercise Price of Derivative	(First) (CKTAR THERAPEUTICS SION BAY BOULEVARD  ISCO  (State) (CTable Security (Instr. 3)  Security (Instr. 3)  2. Conversion or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle)  KTAR THERAPEUTICS  SSION BAY BOULEVARD SOUTH  ISCO  CA  94158  (State) (Zip)  Table I - No  Security (Instr. 3)  Stock  Table II -  Conversion or Exercise Price of Derivative Price of Derivative (Month/Day/Year)  Price of Derivative (Month/Day/Year)	(First) (Middle)  KTAR THERAPEUTICS SSION BAY BOULEVARD SOUTH  ISCO  CA  94158  (State) (Zip)  Table I - Non-Deriv  Security (Instr. 3)  2. Transac Date (Month/Da  Execution Date, if any (Month/Day/Year) Price of Derivative  2. Transaction Date (Month/Day/Year) (Month/Day/Year)	en Jillian B.  (First) (Middle)  3. D  11/1  SISION BAY BOULEVARD SOUTH  (State) (Zip)  Table I - Non-Derivative  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  Conversion or Exercise Price of Derivative (Month/Day/Year)  Price of Derivative (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)	en Jillian B.  (First) (Middle)  KTAR THERAPEUTICS SION BAY BOULEVARD SOUTH  Table I - Non-Derivative Security (Instr. 3)  Table I - Non-Derivative Security (Month/Day/Year)  Table II - Derivative Security (e.g., puts, calls, (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  A. If Amend 2. Transaction Date (e.g., puts, calls, (Month/Day/Year)  2. (State) 3. Transaction Date (e.g., puts, calls, (Month/Day/Year)  A. Deemed Execution Date, if any (Month/Day/Year)  A. Deemed Execution Date, if any (Month/Day/Year)  A. Transaction Code (Instr. 8)	Part of the principle of the principle of the principle of Derivative Security    Conversion of Exercise Price of Derivative Security   Conversion of Exercise Price of Derivative Security   Conversion of Exercise Price of Derivative Security   Conversion of Exercise Price of Derivative Security   Conversion of Exercise Price of Derivative Security   Conversion of Exercise Price of Derivative Security (Month/Day/Year)   Conversion of Exercise Price of Derivative Security (Month/Day/Year)   Conversion Oate (Month/Day/Year)   Conversion O	(First) (Middle)  KTAR THERAPEUTICS SION BAY BOULEVARD SOUTH  Table I - Non-Derivative Securities Action Date (Month/Day/Year)  Security (Instr. 3)  Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, (Month/Day/Year)  2. Transaction Date (if any (Month/Day/Year)  Stock  Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, (Month/Day/Year)  2. Transaction Date (e.g., puts, calls, warrants, (Month/Day/Year)  3. Date of Earliest Trans 11/16/2016  2. Transaction Date (if any (Month/Day/Year))  Stock  Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, (Month/Day/Year)  3. Date of Earliest Trans 11/16/2016  5. Number Of Code (Instr. 8)  5. Number Of Code (Instr. 8)  5. Number Of Code (Instr. 8)  6. Number Of Code (Instr. 8)  6. Number Of Code (Instr. 8)  6. Number Of Code (Instr. 8)  7. Number Of Code (Instr. 8)  8. Nektar There	(First) (Middle)  KTAR THERAPEUTICS SISION BAY BOULEVARD SOUTH  Table I - Non-Derivative Securities Acquired (Month/Day/Year)  Security (Instr. 3)  Table II - Derivative Securities Acquired (Month/Day/Year)  Table II - Derivative Securities Acquired (Rog., puts, calls, warrants, option  Table II - Derivative Securities Acquired, I (e.g., puts, calls, warrants, option  Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  Date  Date  Date	(First) (Middle)  KTAR THERAPEUTICS SIGN BAY BOULEVARD SOUTH  Table I - Non-Derivative Securities Acquired, Disposed of Operivative Securities  Table II - Derivative Securities Acquired, Disposed of Operivative Securities  Table II - Derivative Securities Acquired, Disposed of Operivative Securities  Table II - Derivative Securities Acquired, Disposed of Operivative Securities  Table II - Derivative Securities Acquired, Disposed of Operivative Securities  Table II - Derivative Securities Acquired, Disposed of Operivative Securities  Table II - Derivative Securities Acquired, Disposed of Operivative Securities Acquired (A) or Disposed of Operivative Securities A	CFIRST   (Middle)   START THERAPEUTICS   NK	NEKTAR THERAPEUTICS   NKTR	NEKTAR THERAPEUTICS   NKTR	Security (Instr. 3)   Securities   Securit	Security (Instr. 3)   Security (Instr. 3)   Security (Instr. 3)   Security (Instr. 3)   Table II - Derivative Securities Acquired, Disposed of, or Beneficially of (Month/Day/Year)   Security (Instr. 3)   Security (Inst	NEKTAR THERAPEUTICS   NKTR     Check all appropriate   NKTAR THERAPEUTICS   NKTR     NKTR     NKTAR THERAPEUTICS   NKTR     NKTAR THERAPEUTICS   NKTR     NKTAR THERAPEUTICS   NKTAR   NATIONAL CONTROL OF THE NATIONAL CONTROL OF	Check all applicable   Director   Director   Officer (give title below)	NEKTAR THERAPEUTICS   NKTR     Cheek all applicables   Director   10%		

## **Explanation of Responses:**

- 1. This transaction was executed in multiple trades at prices ranging from \$13.71 to \$14.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
- 2. This number includes 988 shares held by the reporting person in the Issuer's 401(k) plan and 2,250 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

## Remarks:

Mark A. Wilson, Attorney-in-

**Fact** 

\*\* Signature of Reporting Person

11/18/2016

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.